Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Prolexys begins phase I study of PRLX-93936 for solid tumors

Aug. 31, 2007

Lorus completes proof of concept trial of GTI-2040 for AML; begins phase II trial

Aug. 31, 2007

Treanda granted U.S. orphan drug designation for CLL

Aug. 31, 2007

New six-month dosage for MediGene's Eligard receives pan-European approval

Aug. 31, 2007

New Akt inhibitors with antitumor potential described by Pfizer

Aug. 31, 2007

Fast track status granted to Pharmion's oral azacitidine for MDS

Aug. 30, 2007

ALS-357 granted FDA orphan drug designation for metastatic melanoma

Aug. 30, 2007

Biomira initiates phase I trial of PX-478 in patients with advanced metastatic cancers

Aug. 30, 2007

Recent OSI and Shanghai Hengrui patents impart new therapeutic agents for cancer

Aug. 30, 2007

GlaxoSmithKline receives EC approval of Atriance for oncology orphan drug indications

Aug. 29, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...